Ikarian Capital’s Ovid Therapeutics OVID Stock Holding History

Ikarian Capital’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.11M	Sell	2,269,704 -625,000	-22%	-$1.61M	0.66%	44
2026 Q1	$6.43M	Buy	2,894,704 +2,647,146	+1,069%	+$4.73M	0.52%	50
2025 Q4	$404K	Sell	247,558 -848,016	-77%	-$1.31M	0.03%	142
2025 Q3	$1.42M	Buy	+1,095,574	New	+$950K	0.14%	110
2022 Q3	–	Sell	-26,831	Closed	-$59K	–	148
2022 Q2	$59K	Sell	26,831 -711,541	-96%	-$1.72M	0.01%	134
2022 Q1	$2.32M	Buy	738,372 +33,290	+5%	+$105K	0.3%	62
2021 Q4	$2.26M	Sell	705,082 -400,000	-36%	-$1.37M	0.34%	58
2021 Q3	$3.71M	Sell	1,105,082 -19,790	-2%	-$72.2K	0.26%	84
2021 Q2	$4.4M	Hold	1,124,872	–	–	0.36%	74
2021 Q1	$4.52M	Buy	+1,124,872	New	+$3.74M	0.15%	129
2020 Q2	–	Sell	-377,737	Closed	-$1.13M	–	200
2020 Q1	$1.13M	Buy	377,737 +27,737	+8%	+$93.5K	0.08%	116
2019 Q4	$1.45M	Buy	+350,000	New	+$1.11M	0.24%	70

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Ikarian Capital's OVID Position: Q2 2026 in Review

Ikarian Capital reduced its Ovid Therapeutics (OVID) stake by 22% in Q2 2026, selling an estimated $1.61M and leaving 2,269,704 shares worth $6.11M. The position accounts for 0.66% of the portfolio, ranked #44.

Ikarian Capital first reported a position in OVID in Q4 2019 and has held it in 12 quarters since. The position peaked at $6.43M in Q1 2026. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Ikarian Capital held 2,269,704 shares of Ovid Therapeutics worth $6.11M as of Q2 2026.
Ikarian Capital sold 625,000 Ovid Therapeutics shares in Q2 2026, an estimated $1.61M.
Ovid Therapeutics made up 0.66% of Ikarian Capital's portfolio in Q2 2026, its #44 holding.
Ikarian Capital first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 12 quarters since.
Ikarian Capital's Ovid Therapeutics position peaked at $6.43M in Q1 2026.
131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.